Coronary Disease
Conditions
Keywords
coronary disease, atherosclerosis, endothelial function, caffeine, cerebrovascular disease, prevention
Brief summary
Prior work (Chris, M. et al, Clinical Science 2005; 109, 55-60) has demonstrated that drinking a cup of coffee (80-100 mg of caffeine) an hour before endothelium-dependent FMD (flow-mediated dilatation) of the brachial artery, effects endothelial function in healthy adults subjects. This effect might be attributed to caffeine, given that decaffeinated coffee (\<2 mg of caffeine) was not associated with any change in endothelial performance. In the current study we intend to further examine the impact of caffeine on brachial endothelial function among healthy subjects & in patients with proven ischemic heart disease.
Detailed description
Background: Prior work (Chris, M. et al, Clinical Science 2005; 109, 55-60) has demonstrated that drinking a cup of coffee (80-100 mg of caffeine) an hour before endothelium-dependent FMD (flow-mediated dilatation) of the brachial artery, effects endothelial function in healthy adults subjects. This effect might be attributed to caffeine, given that decaffeinated coffee (\<2 mg of caffeine) was not associated with any change in endothelial performance. In the current study we intend to further examine the impact of caffeine on brachial endothelial function among healthy subjects & in patients with proven ischemic heart disease. Aim: To evaluate the impact of 200 mg caffeine tablet intake (equivalent to 2 cups of coffee), compared to placebo on brachial endothelial function in healthy subjects & in patients with proven ischemic heart disease. Methods: 1. Patients will be invited for two endothelial function tests 1 week apart. 2. ECG, heart rate & blood pressure will be recorded at rest prior to each test. 3. Following overnight fasting and discontinuation of all medications for ≥ 12 hours and absence of \> 48 hour caffeine consumption, patients will receive 200 mg of caffeine tablets or placebo, in a double-blind, cross-over study design. An hour later the patient will undergo endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent, nitroglycerin (NTG)-mediated vasodilation will be assessed non-invasively in the brachial artery, using a high resolution (15 MHz) linear array ultrasound. 4. Prior to and after the FMD, blood will be drawn to test caffeine levels, adiponectin, CBC, electrolytes, CRP and lipids.
Interventions
Caffeine 200 mg tablet
Placebo pills
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with documented ischemic heart disease * Healthy subjects who are not heavy regular coffee drinkers
Exclusion criteria
* Patients with unstable angina pectoris * Patients with acute or chronic heart failure * Patients with cardiac arrhythmia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow-mediated dilation (FMD) as surrogate of brachial artery endothelial function | 1-2 hours post caffeine (or placebo) |
Secondary
| Measure | Time frame |
|---|---|
| Markers of inflammation such as hs-CRP, Il6, homocysteine, serum caffeine level | 1-2 hours post caffeine or placebo |
Countries
Israel